Today's Peptide News — October 6, 2026

Eli Lilly reported on September 30, 2026 results from a 48-week, double-blind, placebo-controlled Phase 2b trial of EloraTZP, a combination of the amylin analog eloralintide with tirzepatide, in 367 adults with obesity or overweight and type 2 diabetes in the U.S. and Argentina. Participants on the combination lost up to an average of 54.1 lbs (23.3% of body weight), compared with 34.4 lbs on tirzepatide alone, and A1C fell by up to 2.9% versus 2.4% for tirzepatide.

Gastrointestinal effects predominated and were generally mild or moderate, mostly during dose escalation. Discontinuation rates ranged from 10.8% to 27.0% across the EloraTZP arms. Lilly plans to start Phase 3 studies of a co-formulated product by the end of 2026 with an optimized escalation schedule.

Why it matters: this is among the clearest clinical signals that adding amylin-pathway agonism to an incretin can push weight loss beyond tirzepatide. Suggested PeptideWiki angle: a short explainer on eloralintide as an amylin analog, how amylin and GIP/GLP-1 signaling complement each other, and what the discontinuation rates say about tolerability. Note this is a company release, not a peer-reviewed paper, so frame it as topline data.

An October 6, 2026 commentary from the Independent Institute argues that compounded GLP-1 drugs, distributed through telehealth platforms during the 2022-2025 shortage, reached millions of patients with serious adverse events well under 1% of reported problems, and that private incentives such as registration risk and platform reputation helped police quality.

The piece also notes that in July 2026 the FDA's Pharmacy Compounding Advisory Committee voted to let compounders produce six of seven peptides barred in 2023. The FDA has not finalized that recommendation. This is an opinion piece, so treat its safety framing as one viewpoint.

STAT reported on October 5, 2026 that the stem cell industry is lobbying for the kind of regulatory opening compounded peptides have received under the current administration, including backing from the MAHA movement associated with RFK Jr. Entrepreneur Chuck Meeker predicted FDA roundtables on stem cells before the end of the year.

For peptide readers, the story is a useful read on how far the policy environment has shifted, with substances such as BPC-157 and KPV now part of the compounding discussion.

The 2026 Nobel Prize in Physiology or Medicine was awarded on October 5 to Karl Deisseroth, Peter Hegemann and Georg Nagel for developing optogenetics, a technique that uses light to control and study neurons and brain function.

NBC News reports an early-stage clinical trial in which some people with type 1 diabetes were able to stop insulin therapy after an experimental treatment. The trial is early, so durability and safety in larger groups remain to be shown. Details of the treatment were not retrieved in this run; see the source for specifics.

STAT reports that late-stage trials show an mRNA cancer vaccine reduced melanoma recurrence, and discusses whether the approach will work in other tumor types.

Florida has reported more than 250 dengue cases in 2026, the largest number the continental U.S. has seen in decades, according to The Hill. Separately, CIDRAP notes U.S. measles cases are nearing 4,000 this year.